Safety and efficacy evaluation of ambrisentan in pulmonary hypertension

Carmine Dario Vizza, Francesco Fedele, Beatrice Pezzuto, Lewis J. Rubin

Research output: Contribution to journalArticlepeer-review


Introduction: Pulmonary arterial hypertension (PAH) is characterized by an increase in pulmonary vascular resistance, which can lead to right heart failure and death. Endothelin-1 binding ETA and ETB receptors seem to play a critical role in the pathogenesis and progression of the disease, and oral endothelin receptor antagonists (ERAs) have been shown to be an effective treatment. Bosentan and ETA-selective ambrisentan are the ERAs currently available for PAH treatment. Areas covered: On the basis of the analysis of the literature, this paper addresses the efficacy and safety of ambrisentan in the treatment for PAH. Expert opinion: Ambrisentan has shown an efficacy comparable with other ERAs. Compared with bosentan, ambrisentan seems to have a better safety profile with regards to hepatic safety and drugdrug interactions. On the other hand, ambrisentan shows a higher rate of other adverse events, such as nasal congestion and peripheral edema. Ambrisentan is a viable option for PAH treatment. However, there is still a need for more robust data about long-term mortality, treatment in non-PAH pulmonary hypertension (PH) (such as PH due to left heart disease and PH due to chronic hypoxic lung diseases) and combination therapy.

Original languageEnglish
Pages (from-to)1003-1011
Number of pages9
JournalExpert Opinion on Drug Safety
Issue number6
Publication statusPublished - Nov 2012


  • Ambrisentan
  • Drug safety
  • Endothelin receptor antagonists
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Safety and efficacy evaluation of ambrisentan in pulmonary hypertension'. Together they form a unique fingerprint.

Cite this